CMS Proposal to Expand Medicare and Medicaid Coverage for GLP-1 Drugs

 CMS has proposed expanding Medicare and Medicaid coverage to include GLP-1 receptor agonists for obesity treatment.

Current regulations prevent Medicare from covering these drugs when used solely for weight management, even though some states allow Medicaid coverage.

The high cost of these medications, often exceeding $1,000 per month, limits accessibility for many individuals.

CMS is now proposing to reinterpret statutes, requiring Medicaid and allowing Medicare Part D to cover anti-obesity medications.

The proposal, set for the contract year 2026, would make these drugs accessible to more Americans, improving health and quality of life.

Experts, such as the chief medical officer of the American College of Cardiology, applaud the effort, citing potential benefits for cardiovascular health.

Studies, including the SUMMIT trial and STEP-HFpEF trial, suggest GLP-1 drugs may benefit patients with conditions like HFpEF and cardiometabolic abnormalities.

Despite expanded coverage, challenges remain in determining which patients benefit most from GLP-1 drugs.

Prior authorization processes may also continue to limit seamless access to these therapies.

Stakeholders, including CMS, providers, and patients, must collaborate to identify eligible patients and streamline treatment delivery.

The proposal's future remains uncertain as a new presidential administration takes office in January.

Public comments on the rule change are open until January 27, 2025, via the Federal Register.

---

Key Takeaways

1. Proposed Expansion: CMS aims to expand Medicare and Medicaid coverage for GLP-1 receptor agonists in obesity treatment.
2. Cost Barrier: High drug costs and restrictive policies currently limit access for many patients.
3. Implementation Year: Changes would apply starting in 2026 for Medicare Part D and Medicare Advantage plans.
4. Clinical Benefits: Trials suggest potential cardiovascular and metabolic benefits from these drugs.
5. Collaboration Needed: Stakeholders must work together to optimize patient selection and access.
6. Uncertain Future: The proposal’s success may hinge on policy continuity under the incoming administration.
7. Public Input: Comments on the proposal are being accepted until January 27, 2025.

Learn More